Toru Mukohara

15PUBLICATIONS
93CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Aug 28, 2026
Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Jul 07, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

|Jan 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano

Pageof 3

Frequent Collaborators

4 joint publications

Yoichi Naito

4 joint publications

Nobuaki Matsubara

3 joint publications

Kenichi Harano

3 joint publications

Hiroshi Tanabe